Sequencing novel agents in the treatment of classical Hodgkin lymphoma

References

• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–1607. doi: 10.1056/NEJMoa1408648
   PubMed Web of Science ®Google Scholar
• Andre MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin Lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786–1794. doi: 10.1200/JCO.2016.68.6394
   PubMed Web of Science ®Google Scholar
• Straus DJ, Jung SH, Pitcher B, et al. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood. 2018;132(10):1013–1021. doi: 10.1182/blood-2018-01-827246
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–2429. doi: 10.1056/NEJMoa1510093
   PubMed Web of Science ®Google Scholar
• Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/Computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. 2018;36(5):454–462. doi: 10.1200/JCO.2017.75.2543
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–2189. doi: 10.1200/JCO.2011.38.0410
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319. doi: 10.1056/NEJMoa1411087
   PubMed Web of Science ®Google Scholar
• Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733–3739. doi: 10.1200/JCO.2016.67.3467
   PubMed Web of Science ®Google Scholar
• Hazane Leroyer E, Ziegler C, Moulin C, et al. Filling the gap: the immune therapeutic armamentarium for relapsed/refractory Hodgkin lymphoma. J Clin Med. 2022;11(21):6574. doi: 10.3390/jcm11216574
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–1294. doi: 10.1016/S1470-2045(16)30167-X
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin Lymphoma. J Clin Oncol. 2017;35(19):2125–2132. doi: 10.1200/JCO.2016.72.1316
   PubMed Web of Science ®Google Scholar
• Abramson JS, Arnason JE, LaCasce AS, et al. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. 2019;134(7):606–613. doi: 10.1182/blood.2019001272
   PubMed Web of Science ®Google Scholar
• Kumar A, Casulo C, Advani RH, et al. Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, Unfavorable-Risk Hodgkin Lymphoma. J Clin Oncol. 2021;39(20):2257–2265. doi: 10.1200/JCO.21.00108
   PubMed Web of Science ®Google Scholar
• Fornecker LM, Lazarovici J, Aurer I, et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial. J Clin Oncol. 2023;41(2):327–335. doi: 10.1200/JCO.21.01281
   PubMed Web of Science ®Google Scholar
• Abramson JS, Bengston E, Redd R, et al. Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma. Blood Adv. 2023;7(7):1130–1136. doi: 10.1182/bloodadvances.2022008420
   PubMed Web of Science ®Google Scholar
• Bröckelmann PJ, Bühnen I, Meissner J, et al. Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin Lymphoma: final analysis of the randomized German Hodgkin study group phase II NIVAHL trial. J Clin Oncol. 2023;41(6):1193–1199. doi: 10.1200/JCO.22.02355
   PubMed Web of Science ®Google Scholar
• Allen PB, Savas H, Evens AM, et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood. 2021;137(10):1318–1326. doi: 10.1182/blood.2020007400
   PubMed Web of Science ®Google Scholar
• Lynch RC, Ujjani CS, Poh C, et al. Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma. Blood. 2023;141(21):2576–2586. doi: 10.1182/blood.2022019254
   PubMed Web of Science ®Google Scholar
• Lee HJ, Abramson JS, Barlett NL, et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early stage classic Hodgkin lymphoma: interim efficacy and safety results from the single-arm phase 2 study (SGN35-027 part C). In: American Society of Hematology 64th Annual Meeting & Exposition 2022. (Ed.^(Eds); 2022; New Orleans, Louisiana: Poster presentation. Abstract no 4230.
   Google Scholar
• Park SI, Ansell SM, Giri S, et al. Frontline PET-Directed therapy with brentuximab vedotin plus AVD followed by nivolumab consolidation in patients with limited stage Hodgkin lymphoma (ACCRU-LY-1601). In: American Society of Hematology 64th Annual Meeting & Exposition 2022 (Ed.^(Eds); 2022; New Orleans, (LA): Oral presentation. Abstract no 728.
   Google Scholar
• Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–1356. doi: 10.1016/S1470-2045(13)70501-1
   PubMed Web of Science ®Google Scholar
• Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–344. doi: 10.1056/NEJMoa1708984
   PubMed Web of Science ®Google Scholar
• Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2022;387(4):310–320. doi: 10.1056/NEJMoa2206125
   PubMed Web of Science ®Google Scholar
• Straus D, Collins G, Walewski J, et al. Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Leuk Lymphoma. 2020;61(12):2931–2938. doi: 10.1080/10428194.2020.1791846
   PubMed Web of Science ®Google Scholar
• Ramchandren R, Domingo-Domenech E, Rueda A, et al. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study. J Clin Oncol. 2019;37(23):1997–2007. doi: 10.1200/JCO.19.00315
   PubMed Web of Science ®Google Scholar
• Lynch RC, Ujjani CS, Poh C, et al. Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma. Blood. 2023. doi: 10.1182/blood.2022019254
   PubMedGoogle Scholar
• Herrera AF, LeBlanc ML, Castellino SM, et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). J Clin Oncol. 2023;41(17_suppl):LBA4–LBA4. doi: 10.1200/JCO.2023.41.17_suppl.LBA4
   Web of Science ®Google Scholar
• Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed or refractory (R/R) classical Hodgkin lymphoma after autologous transplantation: 5-year overall survival from the phase 2 checkmate 205 study. Hematol Oncol. 2021;39(S2). doi: 10.1002/hon.74_2879
   Google Scholar
• Damaschin C, Goergen H, Kreissl S, et al. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin study group. Leukemia. 2022;36(2):580–582. doi: 10.1038/s41375-021-01386-z
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Plutschow A, Kreissl S, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin study group. Lancet Oncol. 2017;18(12):1680–1687. doi: 10.1016/S1470-2045(17)30696-4
   PubMed Web of Science ®Google Scholar
• Borchmann P, Moccia A, Greil R, et al. Treatment related morbidity in patients with classical Hodgkin lymphoma: results of the ongoing, randomized phase III HD21 trial by German Hodgkin study group. In: American Society of Hematology 64th Annual Meeting & Exposition 2022 (Ed.^(Eds); 2022; New Orleans, (LA): Oral presentation. Abstract no 317.
   Google Scholar
• Borchmann P, Moccia AA, Greil R, et al. BRECADD is non-inferior to eBEACOPP in patients with advanced stage classical Hodgkin lymphoma: efficacy results of the GHSG phase III HD21 trial. Hematol Oncol. 2023;41(S2):881–882. doi: 10.1002/hon.3196_LBA5
   Google Scholar
• Lee HJ, Flinn IW, Melear J, et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for advanced-stage classical Hodgkin Lymhoma: updated efficacy and safety results from single-arm phase 2 study (SGN35-027 part B). In: American Society of Hematology 64th Annual Meeting & Exposition 2022. (Ed.^(eds); 2022; New Orleans, (LA): Oral presentation. Abstract no 314.
   Google Scholar
• Mei M, Herrera AF. The next frontier: enter PD-1 and exit PET scans? Blood. 2023;141(21):2545–2546. doi: 10.1182/blood.2023020326
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136–2140. doi: 10.1016/j.bbmt.2015.07.018
   PubMed Web of Science ®Google Scholar
• Herrera AF, Palmer J, Martin P, et al. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2018;29(3):724–730. doi: 10.1093/annonc/mdx791
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Schoder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284–292. doi: 10.1016/S1470-2045(15)70013-6
   PubMed Web of Science ®Google Scholar
• Lynch RC, Cassaday RD, Smith SD, et al. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Lancet Haematol. 2021;8(8):e562–e571. doi: 10.1016/S2352-3026(21)00170-8
   PubMed Web of Science ®Google Scholar
• LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40–48. doi: 10.1182/blood-2017-11-815183
   PubMed Web of Science ®Google Scholar
• LaCasce AS, Bociek RG, Sawas A, et al. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. Br J Haematol. 2020;189(3):e86–e90. doi: 10.1111/bjh.16499
   PubMed Web of Science ®Google Scholar
• Broccoli A, Argnani L, Botto B, et al. First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. Blood Cancer J. 2019;9(12):100. doi: 10.1038/s41408-019-0265-x
   PubMedGoogle Scholar
• Hagenbeek A, Mooij H, Zijlstra J, et al. Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the HOVON/LLPC transplant BRaVE study. Haematologica. 2019;104(4):e151–e153. doi: 10.3324/haematol.2018.196899
   PubMed Web of Science ®Google Scholar
• Kersten MJ, Driessen J, Zijlstra JM, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC transplant BRaVE study. Haematologica. 2021;106(4):1129–1137. doi: 10.3324/haematol.2019.243238
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO group). Ann Oncol. 2019;30(4):612–620. doi: 10.1093/annonc/mdz009
   PubMed Web of Science ®Google Scholar
• Driessen J, de Wit F, Herrera AF, et al. Effect of brentuximab vedotin addition to chemotherapy and prognostic factors in patients with relapsed/refractory Hodgkin lymphoma: a large multi-trial analysis based on Individual patient data. In: American Society of Hematology 63rd Annual Meeting & Exposition 2021. (Ed.^(eds); 2021; Oral presentation: Atlanta, GA. Abstract no 879.
   Google Scholar
• Desai SH, Spinner MA, David K, et al. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. Am J Hematol. 2023;98(3):464–471. doi: 10.1002/ajh.26827
   PubMed Web of Science ®Google Scholar
• Sureda-Balari A, Terol MJ, Domingo-Domènech E, et al. T098: brentuximab vedotin plus ESHAP (BRESHAP) versus ESHAP in patients with relapsed or refractory classical Hodgkin’s lymphoma. Interim results of the BRESELIBET prospective Clinical trial. In International symposium on Hodgkin Lymphoma ISHL12. (Ed.^(eds), 2022; Cologne, Germany: p. T098.
   Google Scholar
• Armand P, Kuruvilla J, Michot J-M, et al. KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. Blood Adv. 2020;4(12):2617–2622. doi: 10.1182/bloodadvances.2019001367
   PubMed Web of Science ®Google Scholar
• Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428–1439. doi: 10.1200/JCO.2017.76.0793
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Shah G, Schoder H, et al. Phase II trial of pembrolizumab plus Gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin Lymphoma. J Clin Oncol. 2021;39(28):3109–3117. doi: 10.1200/JCO.21.01056
   PubMed Web of Science ®Google Scholar
• Mei MG, Lee HJ, Palmer JM, et al. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022;139(25):3605–3616. doi: 10.1182/blood.2022015423
   PubMed Web of Science ®Google Scholar
• Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183–1194. doi: 10.1182/blood-2017-10-811224
   PubMed Web of Science ®Google Scholar
• Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021;138(6):427–438. doi: 10.1182/blood.2020009178
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Hong F, Ambinder RF, et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020;7(9):e660–e670. doi: 10.1016/S2352-3026(20)30221-0
   PubMed Web of Science ®Google Scholar
• Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–1566. doi: 10.1182/blood-2016-02-699850
   PubMed Web of Science ®Google Scholar
• Armand P, Zinzani PLL, Lee HJ, et al. Five-year follow-up of keynote-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). Blood. 2021;138(Supplement 1):1366–1366. doi: 10.1182/blood-2021-147881
   Web of Science ®Google Scholar
• Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144–1153. doi: 10.1182/blood.2019000324
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021;22(4):512–524. doi: 10.1016/S1470-2045(21)00005-X
   PubMedGoogle Scholar
• Goodman KA, Riedel E, Serrano V, et al. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin’s lymphoma. J Clin Oncol. 2008;26(32):5240–5247. doi:10.1200/JCO.2007.15.5507
   PubMed Web of Science ®Google Scholar
• Ferme C, Mounier N, Divine M, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin’s disease in relapse or failure after initial chemotherapy: results of the groupe d’Etudes des lymphomes de l’Adulte H89 trial. J Clin Oncol. 2002;20(2):467–475. doi: 10.1200/JCO.20.2.467
   PubMed Web of Science ®Google Scholar
• Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54(11):2531–2533. doi: 10.3109/10428194.2013.798868
   PubMed Web of Science ®Google Scholar
• Santoro A, Mazza R, Pulsoni A, et al. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2020;4(1):136–140. doi: 10.1182/bloodadvances.2019000984
   PubMed Web of Science ®Google Scholar
• Puig N, Pintilie M, Seshadri T, et al. Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin’s lymphoma. Haematologica. 2010;95(9):1496–1502. doi: 10.3324/haematol.2009.019943
   PubMed Web of Science ®Google Scholar
• Villa D, Seshadri T, Puig N, et al. Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin’s lymphoma resistant to platinum-containing first-line salvage chemotherapy. Haematologica. 2012;97(5):751–757. doi: 10.3324/haematol.2011.047670
   PubMed Web of Science ®Google Scholar
• Song Y, Guo Y, Huang H, et al. Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Expert Rev Hematol. 2021;14(9):867–875. doi: 10.1080/17474086.2021.1942831
   PubMed Web of Science ®Google Scholar
• Salihoglu A, Elverdi T, Karadogan I, et al. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol. 2015;94(3):415–420. doi: 10.1007/s00277-014-2215-9
   PubMed Web of Science ®Google Scholar
• Ozbalak M, Salihoglu A, Soysal T, et al. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience. Ann Hematol. 2020;99(2):301–307. doi: 10.1007/s00277-019-03899-1
   PubMed Web of Science ®Google Scholar
• Bekoz H, Karadurmus N, Paydas S, et al. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann Oncol. 2017;28(10):2496–2502. doi: 10.1093/annonc/mdx341
   PubMed Web of Science ®Google Scholar
• Bekoz H, Ozbalak M, Karadurmus N, et al. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann Hematol. 2020;99(11):2565–2576. doi: 10.1007/s00277-020-04077-4
   PubMed Web of Science ®Google Scholar
• Gaudio F, Loseto G, Bozzoli V, et al. A real-world analysis of PD1 blockade from the rete ematologica pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma. Ann Hematol. 2023;102(2):385–392. doi: 10.1007/s00277-023-05100-0
   PubMed Web of Science ®Google Scholar
• Momotow J, Buhnen I, Trautmann-Grill K, et al. Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: a German Hodgkin study group multicentre real-world analysis. Br J Haematol. 2022;198(2):401–404. doi: 10.1111/bjh.18231
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Ramchandren R, Santoro A, et al. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2022;6(2):590–599. doi: 10.1182/bloodadvances.2021004970
   PubMed Web of Science ®Google Scholar
• Spinner MA, Sica RA, Tamaresis JS, et al. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood. 2023;141(22):2727–2737. doi: 10.1182/blood.2022018827
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–1862. doi: 10.1016/S0140-6736(15)60165-9
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Chen R, Armand P, et al. Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leuk Lymphoma. 2020;61(4):950–954. doi: 10.1080/10428194.2019.1702178
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7(1):24. doi: 10.1186/1756-8722-7-24
   PubMedGoogle Scholar
• Ansell SM, Armand P, Timmerman JM, et al. P125 (0116) nivolumab re-treatment in patients with relapsed/refractory Hodgkin lymphoma. In: 11th international symposium on Hodgkin Lymphoma. (Ed.^(eds); 2018; Oral presentation: Cologne, Germany. Abstract no P125 (O116).
   Google Scholar
• Manson G, Brice P, Herbaux C, et al. Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation. Haematologica. 2020;105(11):2664–2666. doi: 10.3324/haematol.2019.242529
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642. doi: 10.1182/blood-2018-07-861641
   PubMed Web of Science ®Google Scholar
• Kanate AS, Kumar A, Dreger P, et al. Maintenance therapies for Hodgkin and non-Hodgkin Lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the lymphoma Working Party of EBMT. JAMA Oncol. 2019;5(5):715–722. doi: 10.1001/jamaoncol.2018.6278
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Nademanee A, Masszi T, et al. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. Br J Haematol. 2016;175(5):860–867. doi: 10.1111/bjh.14316
   PubMed Web of Science ®Google Scholar
• Marouf A, Cottereau AS, Kanoun S, et al. Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study. Haematologica. 2022;107(7):1681–1686. doi: 10.3324/haematol.2021.279564
   PubMed Web of Science ®Google Scholar
• Massaro F, Pavone V, Stefani PM, et al. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. Hematol Oncol. 2022;40(1):31–39. doi: 10.1002/hon.2939
   PubMed Web of Science ®Google Scholar
• Akay OM, Ozbalak M, Pehlivan M, et al. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: multicenter retrospective study. Hematol Oncol. 2021;39(4):498–505. doi: 10.1002/hon.2897
   PubMed Web of Science ®Google Scholar
• Wagner CB, Boucher K, Nedved A, et al. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica. 2023. doi: 10.3324/haematol.2023.282780
   Web of Science ®Google Scholar
• Armand P, Chen YB, Redd RA, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134(1):22–29. doi: 10.1182/blood.2019000215
   PubMed Web of Science ®Google Scholar
• Herrera AF, Chen L, Nieto Y, et al. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. Lancet Haematol. 2023;10(1):e14–e23. doi: 10.1016/S2352-3026(22)00318-0
   PubMed Web of Science ®Google Scholar
• Federico M, Fortpied C, Stepanishyna Y, et al. Early FDG-PET adapted treatment of limited stage hodgkin lymphoma (HL): 10Y long term follow-up analysis of the randomized intergroup EORTC/LYSA/FIL H10 trial. Hematol Oncol. 2023;41(S2):159–160. doi: 10.1002/hon.3163_105
   PubMedGoogle Scholar
• Borchmann P, Plutschow A, Kobe C, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(2):223–234. doi: 10.1016/S1470-2045(20)30601-X
   PubMed Web of Science ®Google Scholar
• Fuchs M, Goergen H, Kobe C, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the International, randomized phase III HD16 trial by the German Hodgkin study group. J Clin Oncol. 2019;37(31):2835–2845. doi: 10.1200/JCO.19.00964
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–1054. doi: 10.1016/0140-6736(93)92411-L
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–2071. doi: 10.1016/S0140-6736(02)08938-9
   PubMed Web of Science ®Google Scholar
• Josting A, Nogova L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin lymphoma study group. J Clin Oncol. 2005;23(7):1522–1529. doi: 10.1200/JCO.2005.05.022
   PubMed Web of Science ®Google Scholar
• Goda JS, Massey C, Kuruvilla J, et al. Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant. Int J Radiat Oncol Biol Phys. 2012;84(3):e329–335. doi: 10.1016/j.ijrobp.2012.04.007
   PubMed Web of Science ®Google Scholar
• Constine LS, Yahalom J, Ng AK, et al. The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2018;100(5):1100–1118. doi: 10.1016/j.ijrobp.2018.01.011
   PubMed Web of Science ®Google Scholar
• Merryman RW, Castagna L, Giordano L, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021;35(9):2672–2683. doi: 10.1038/s41375-021-01193-6
   PubMed Web of Science ®Google Scholar
• Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical trials group. Ann Oncol. 2003;14(12):1762–1767. doi: 10.1093/annonc/mdg496
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol. 2007;18(6):1071–1079. doi: 10.1093/annonc/mdm090
   PubMed Web of Science ®Google Scholar
• Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92(1):35–41. doi: 10.3324/haematol.10661
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616–623. doi: 10.1182/blood.V97.3.616
   PubMed Web of Science ®Google Scholar
• Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol. 2002;13(10):1628–1635. doi: 10.1093/annonc/mdf221
   PubMed Web of Science ®Google Scholar
• Aparicio J, Segura A, Garcera S, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol. 1999;10(5):593–595. doi: 10.1023/A:1026454831340
   PubMed Web of Science ®Google Scholar
• Santoro A, Bredenfeld H, Devizzi L, et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol. 2000;18(13):2615–2619. doi: 10.1200/JCO.2000.18.13.2615
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Hamlin PA Jr., Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31(4):456–460. doi: 10.1200/JCO.2012.45.3308
   PubMed Web of Science ®Google Scholar
• Little R, Wittes RE, Longo DL, et al. Vinblastine for recurrent Hodgkin’s disease following autologous bone marrow transplant. J Clin Oncol. 1998;16(2):584–588. doi:10.1200/JCO.1998.16.2.584
   PubMed Web of Science ®Google Scholar
• Devizzi L, Santoro A, Bonfante V, et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin’s disease. Ann Oncol. 1994;5(9):817–820. doi: 10.1093/oxfordjournals.annonc.a059010
   PubMed Web of Science ®Google Scholar
• Herrera AF, Carlo-Stella C, Collins GP, et al. Preliminary results of a phase 2 study of Camidanlumab Tesirine (Cami), a novel Pyrrolobenzodiazepine-based antibody-drug conjugate, in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136(Supplement 1):21–23. doi: 10.1182/blood-2020-137451
   Web of Science ®Google Scholar
• Ramos CA, Grover NS, Beaven AW, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38(32):3794–3804. doi: 10.1200/JCO.20.01342
   PubMed Web of Science ®Google Scholar
• Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32(8):798–808. doi: 10.1200/JCO.2013.51.5304
   PubMed Web of Science ®Google Scholar
• Ramos CA, Quach DH, Lulla PD, et al. Off-the-shelf CD30.CAR-Modified Epstein-Barr virus-specific T cells (CD30.CAR EBVSTS) provide a safe and effective therapy for patients with Hodgkin lymphoma (HL). Hematol Oncol. 2023;41(S2):83–85. doi: 10.1002/hon.3163_47
   Google Scholar
• Bartlett NL, Herrera AF, Domingo-Domenech E, et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136(21):2401–2409. doi: 10.1182/blood.2019004701
   PubMed Web of Science ®Google Scholar
• Lavie D, Johnson N, Borchmann P, et al. An open-label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti-PD-1 treatment. Hematol Oncol. 2023;41(S2):364–366. doi: 10.1002/hon.3164_263
   Google Scholar
• Clancy-Thompson E, Perry T, Pryts S, et al. 461 Generation of AZD7789, a novel PD-1 and TIM-3 targeting bispecific antibody, which binds to a differentiated epitope of TIM-3. Journal For ImmunoTherapy Of Cancer. 2022;10(Suppl 2):A481–A481.
   Google Scholar